We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Will a Change of Diet Prevent Cancer?

By LabMedica International staff writers
Posted on 30 Jun 2011
Cancer researchers have found that a diet low in carbohydrates and high in protein reduced the risk of developing some types of cancer in a mouse model.

Investigators at the University of British Columbia (Vancouver, Canada) postulated that fast growing cancer cells should require significantly more glucose to grow and thrive than normal cells. More...
Furthermore, they reasoned that restricting glucose intake might slow or prevent tumor growth.

To examine this concept they implanted human tumor cells into various strains of mice, some of which were also growing mouse tumors. The mice were separated into two groups. One group was fed a typical Western diet, containing about 55% carbohydrate, 23% protein, and 22% fat. The second group received a highly modified diet (low CHO diet) that contained 15% carbohydrate, 58% protein, and 26% fat.

Results published in the June 14, 2011, online edition of the journal Cancer Research revealed that both mouse and human tumors grew more slowly in the mice that received the low CHO diet. While there was no significant weight difference between the tumor-bearing mice on the low CHO or Western diets, the low CHO-fed mice exhibited lower blood glucose, insulin, and lactate.

Combining a low CHO diet with chemotherapy increased the effect of the mTOR inhibitor CCI-779 and especially that of the potent anti-inflammatory COX-2 inhibitor Celebrex. In a genetically engineered mouse model of HER-2/neu–induced mammary cancer, tumor penetrance in mice on a Western diet was nearly 50% by the age of one year whereas no tumors were detected in mice on the low CHO diet.

Only one mouse on the Western diet achieved a normal life span, due to cancer-associated deaths, while more than 50% of the mice on the low CHO diet reached or exceeded the normal life span. "This shows that something as simple as a change in diet can have an impact on cancer risk," said senior author Dr. Gerald Krystal, professor of pathology and laboratory medicine at the University of British Columbia.

Related Links:

University of British Columbia




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Manual Pipetting Aid
Pipette Controllers macro
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.